Compare KRMD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | NYXH |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.5M | 161.9M |
| IPO Year | 2019 | 2021 |
| Metric | KRMD | NYXH |
|---|---|---|
| Price | $4.44 | $1.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $6.50 | ★ $9.33 |
| AVG Volume (30 Days) | 153.7K | ★ 525.3K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,127,366.00 | N/A |
| Revenue This Year | $20.32 | $213.98 |
| Revenue Next Year | $17.37 | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.91 | $1.26 |
| 52 Week High | $6.61 | $8.59 |
| Indicator | KRMD | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 62.63 | 39.17 |
| Support Level | $3.84 | $1.26 |
| Resistance Level | $4.68 | $3.36 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 91.67 | 81.82 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.